Stocktoria
Climb Bio, Inc. CLYM
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-08-10
Climb Bio, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D expense | $46.7M | $14.3M | $15.4M | $26.2M | $23.3M | $8.8M |
| Operating income | -$67.9M | -$82.0M | -$40.3M | -$45.1M | -$35.7M | -$20.9M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.9M | -$73.9M | -$35.1M | -$45.2M | -$47.5M | -$20.7M |
| EPS (diluted) | $-0.88 | $-1.53 | $-1.30 | $-1.72 | $-4.24 | — |
| Operating cash flow | -$54.4M | -$15.6M | -$20.6M | -$37.4M | -$36.1M | -$14.1M |
| Free cash flow | -$54.5M | -$15.6M | — | — | — | — |
| Cash & equivalents | $35.7M | $87.2M | $93.1M | $43.6M | $46.9M | $20.5M |
| Total assets | $167.7M | $217.2M | $110.5M | $135.0M | $173.2M | $24.6M |
| Total liabilities | $7.3M | $5.3M | $2.9M | $6.3M | $6.0M | $3.1M |
| Shareholders' equity | $160.5M | $211.9M | $107.6M | $128.7M | $167.2M | -$25.0M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.